Compare SBH & ABSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SBH | ABSI |
|---|---|---|
| Founded | 1964 | 2011 |
| Country | United States | United States |
| Employees | N/A | 140 |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.4B |
| IPO Year | 2006 | 2021 |
| Metric | SBH | ABSI |
|---|---|---|
| Price | $16.67 | $8.25 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 11 |
| Target Price | ★ $17.00 | $14.90 |
| AVG Volume (30 Days) | 1.3M | ★ 4.3M |
| Earning Date | 11-12-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 32.17 | 10.64 |
| EPS | ★ 1.43 | N/A |
| Revenue | ★ $3,701,424,000.00 | $4,534,000.00 |
| Revenue This Year | $0.82 | $39.03 |
| Revenue Next Year | $1.51 | $310.91 |
| P/E Ratio | $11.97 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $11.54 | $2.24 |
| 52 Week High | $17.92 | $12.06 |
| Indicator | SBH | ABSI |
|---|---|---|
| Relative Strength Index (RSI) | 54.52 | 40.79 |
| Support Level | $15.09 | $8.17 |
| Resistance Level | $17.01 | $11.73 |
| Average True Range (ATR) | 0.54 | 0.79 |
| MACD | 0.04 | -0.25 |
| Stochastic Oscillator | 56.81 | 1.60 |
Sally Beauty Holdings Inc is a professional beauty-products retailer based in the United States. The company operates throughout the United States, Puerto Rico, the United Kingdom, Belgium, Canada, Chile, Mexico, Peru, France, Ireland, Spain, Germany, Netherlands, and other geographical regions. The company operates through two business segments: Sally Beauty Supply and Beauty Systems Group. The products offered by the company include hair color and care, hair dryers and hair-styling appliances, nail care, skin care, and others.
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process. Its lead product candidate, ABS-201, is an anti-prolactin receptor (PRLR) antibody engineered with an extended half-life to support a patient-friendly dosing interval.